Amol Akhade/LinkedIn
Jan 7, 2025, 11:59
Amol Akhade: What is interesting in ASC0GI 25?
Amol Akhade, a Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals shared a post on LinkedIn:
“What is interesting in ASC0GI 25?
- Nivo vs Nivo -Ipi -Checkmate 8HW.
- Blood-based screening for CRC – debate.
- Adjuvant chemotherapy vs CTRT for GB (RCT from AIIMS, New Delhi, India).
- Trastuzumab plus Pertuzumab in Perioperative chemotherapy in Her2 positive stomach cancer.
What’s your take ?”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specializes in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplants.
More posts featuring Amol Akhade.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 7, 2025, 11:59
Jan 7, 2025, 11:32
Jan 7, 2025, 11:14
Jan 7, 2025, 11:00
Jan 7, 2025, 10:56
Jan 7, 2025, 10:33